Prostate Specific Membrane Antigen Targeted Positron Emission Tomography of Primary Prostate Cancer: Assessing Accuracy with Whole Mount Pathology

被引:15
|
作者
Bahler, Clinton D. [1 ]
Green, Mark [2 ]
Hutchins, Gary D. [2 ]
Cheng, Liang [3 ]
Magers, Martin J. [3 ]
Fletcher, James [2 ]
Koch, Michael O. [1 ]
机构
[1] Indiana Univ, Dept Urol, Indianapolis, IN 46204 USA
[2] Indiana Univ, Dept Radiol, Indianapolis, IN 46204 USA
[3] Indiana Univ, Dept Pathol, Indianapolis, IN 46204 USA
基金
美国国家卫生研究院;
关键词
prostatic neoplasms; positron-emission tomography; pathology; surgical; risk; early detection of cancer; RADICAL PROSTATECTOMY; GLEASON PATTERN-4; TUMOR VOLUME; MEN; PROGRESSION; BIOPSY; PERCENTAGE; PREDICTOR; PET/CT;
D O I
10.1097/JU.0000000000000501
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluated which lesions are detected and missed on [Ga-68]Ga-PSMA (prostate specific membrane antigen)-11 positron emission tomography in patients with primary prostate cancer. Materials and Methods: Patients undergoing radical prostatectomy were enrolled in this prospective observational study. Patients underwent [Ga-68] Ga-PSMA-11 positron emission tomography/computerized tomography or positron emission tomography/magnetic resonance imaging prior to surgery and received a dose of [Ga-68] Ga-PSMA-11 intraoperatively for positron emission tomography of extirpated specimens. Whole mount pathology was performed with lesion and intralesion based analysis to determine the characteristics of lesions detected or not detected by PSMA positron emission tomography. Lesion volume was determined by planimetry and clinically significant lesion volume was calculated as lesion volume x fraction pattern 4/5. Results: On whole mount analysis 30 cancerous lesions were found in a total of 15 patients, including 4, 15, 4, 1 and 6 which were Grade Group 1, 2, 3, 4 and 5, respectively. PSMA-positron emission tomography detected 100% of primary/index lesions and 8 of 11 (82%) secondary lesions. All Grade Group 3-5 lesions were detected vs 12 of 15 Grade Group 2 lesions. When comparing Grade Group 2 vs 3-5, lesion size was similar (p = 0.48) but the standardized uptake value was lower for Grade Group 2 vs 3-5 (5.3 vs 7.9, p = 0.03). The 3 missed lesions showed 10% or less of pattern 4 and a Gleason pattern 4/5 volume of less than 0.1 cm(3). Conclusions: PSMA positron emission tomography detected 100% of primary/index lesions in this study. The 3 missed secondary lesions were small and had a low percent of pattern 4. This argues for further study to better understand what defines clinically significant prostate cancer, which would assist in determining whether small lesions that become challenging to detect by [Ga-68]Ga-PSMA-11 positron emission tomography confer a risk to the patient.
引用
收藏
页码:92 / 99
页数:8
相关论文
共 50 条
  • [31] Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer
    Fendler, Wolfgang P.
    Weber, Manuel
    Iravani, Amir
    Hofman, Michael S.
    Calais, Jeremie
    Czernin, Johannes
    Ilhan, Harun
    Saad, Fred
    Small, Eric J.
    Smith, Matthew R.
    Perez, Paola M.
    Hope, Thomas A.
    Rauscher, Isabel
    Londhe, Anil
    Lopez-Gitlitz, Angela
    Cheng, Shinta
    Maurer, Tobias
    Herrmann, Ken
    Eiber, Matthias
    Hadaschik, Boris
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7448 - 7454
  • [32] Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography
    Kneebone, Andrew
    Hruby, George
    Ainsworth, Hannah
    Byrne, Keelan
    Brown, Chris
    Guo, Linxin
    Guminski, Alexander
    Eade, Thomas
    EUROPEAN UROLOGY ONCOLOGY, 2018, 1 (06): : 531 - 537
  • [33] Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study
    Gorin, Michael A.
    Rowe, Steven P.
    Patel, Hiten D.
    Vidal, Igor
    Mana-ay, Margarita
    Javadi, Mehrbod S.
    Solnes, Lilja B.
    Ross, Ashley E.
    Schaeffer, Edward M.
    Bivalacqua, Trinity J.
    Partin, Alan W.
    Pienta, Kenneth J.
    Szabo, Zsolt
    De Marzo, Angelo M.
    Pomper, Martin G.
    Allaf, Mohamad E.
    JOURNAL OF UROLOGY, 2018, 199 (01) : 126 - 132
  • [34] 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review
    Corfield, Julia
    Perera, Marlon
    Bolton, Damien
    Lawrentschuk, Nathan
    WORLD JOURNAL OF UROLOGY, 2018, 36 (04) : 519 - 527
  • [35] Defining Prostatic Vascular Pedicle Recurrence and the Anatomy of Local Recurrence of Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography
    Dundee, Philip
    Furrer, Marc A.
    Corcoran, Niall M.
    Peters, Justin
    Pan, Henry
    Ballok, Zita
    Ryan, Andrew
    Guerrieri, Mario
    Costello, Anthony J.
    EUROPEAN UROLOGY OPEN SCIENCE, 2022, 41 : 116 - 122
  • [36] 68Gallium-Prostate-Specific Membrane Antigen PET/Computed Tomography for Primary and Secondary Staging in Prostate Cancer
    Chaloupka, Michael
    Herlemann, Annika
    D'Anastasi, Melvin
    Cyran, Clemens C.
    Ilhan, Harun
    Gratzke, Christian
    Stief, Christian G.
    UROLOGIC CLINICS OF NORTH AMERICA, 2017, 44 (04) : 557 - +
  • [37] Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis
    Lopci, Egesta
    Lughezzani, Giovanni
    Castello, Angelo
    Saita, Alberto
    Colombo, Piergiuseppe
    Hurle, Rodolfo
    Peschechera, Roberto
    Benetti, Alessio
    Zandegiacomo, Silvia
    Pasini, Luisa
    Casale, Paolo
    Pietro, Diana
    Bevilacqua, Giulio
    Balzarini, Luca
    Buffi, Nicolo Maria
    Guazzoni, Giorgio
    Lazzeri, Massimo
    EUROPEAN UROLOGY FOCUS, 2021, 7 (04): : 764 - 771
  • [38] Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology
    Kalapara, Arveen A.
    Ballok, Zita E.
    Ramdave, Shakher
    O'Sullivan, Richard
    Ryan, Andrew
    Konety, Badrinath
    Grummet, Jeremy P.
    Frydenberg, Mark
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (03): : 314 - 320
  • [39] Detection and localisation of primary prostate cancer using 68gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology
    Kalapara, Arveen A.
    Nzenza, Tatenda
    Pan, Henry Y. C.
    Ballok, Zita
    Ramdave, Shakher
    O'Sullivan, Richard
    Ryan, Andrew
    Cherk, Martin
    Hofman, Michael S.
    Konety, Badrinath R.
    Lawrentschuk, Nathan
    Bolton, Damien
    Murphy, Declan G.
    Grummet, Jeremy P.
    Frydenberg, Mark
    BJU INTERNATIONAL, 2020, 126 (01) : 83 - 90
  • [40] Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer
    Markowski, Mark C.
    Sedhom, Ramy
    Fu, Wei
    Gray, Javaughn Corey R.
    Eisenberger, Mario A.
    Pomper, Martin G.
    Pienta, Kenneth J.
    Gorin, Michael A.
    Rowe, Steven P.
    JOURNAL OF UROLOGY, 2020, 204 (03) : 496 - 502